Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUST1O)

• DTT Name: Phosphodiesterase (PDE)
• Synonyms: Human phosphodiesterase
• Gene Name: PDE
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Phosphoric diester hydrolase
• UniProt ID: NOUNIPROTAC
• TTD ID: T92138
• Function: Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.

Molecular Interaction Atlas (MIA) of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M-518101	DMZ6VD5	Plaque psoriasis	EA90.0	Phase 3	[2]
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[1]

9 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Piroximone	DMQXJDM	Cardiac failure	BD10-BD13	Discontinued in Phase 3	[3]
AA-2379	DM78623	Inflammation	1A00-CA43.1	Discontinued in Phase 2	[4]
HN-10200	DMYJ1ZB	Cardiac failure	BD10-BD13	Discontinued in Phase 2	[5]
TIBENELAST	DMYH2PU	Asthma	CA23	Discontinued in Phase 2	[6]
ALBIFYLLINE	DMVBKLO	Sepsis	1G40-1G41	Discontinued in Phase 1	[7]
BBB-022	DMITV4F	Cerebrovascular ischaemia	8B1Z	Terminated	[8]
Isomazole	DM4YJ2W	Asthma	CA23	Terminated	[9]
JTT-608	DMZBNHC	Diabetic complication	5A2Y	Terminated	[10]
Sch-45752	DME9Q3V	Asthma	CA23	Terminated	[11]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DPN-205-734	DMSRUKQ	Cardiac disease	BA00-BE2Z	Investigative	[12]

References

• [1] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
• [4] Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
• [5] HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
• [6] Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
• [7] Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
• [8] Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
• [9] Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
• [10] JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.
• [11] SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
• [12] Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60.